Display Settings:

Format

Send to:

Choose Destination
We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
    Arthritis Res. 2002;4(5):290-5. Epub 2002 May 7.

    Autoantibody profiling for the study and treatment of autoimmune disease.

    Source

    Department of Medicine, Division of Rheumatology and Immunology, Stanford University School of Medicine, California, USA.

    Abstract

    Proteomics technologies enable profiling of autoantibody responses using biological fluids derived from patients with autoimmune disease. They provide a powerful tool to characterize autoreactive B-cell responses in diseases including rheumatoid arthritis, multiple sclerosis, autoimmune diabetes, and systemic lupus erythematosus. Autoantibody profiling may serve purposes including classification of individual patients and subsets of patients based on their 'autoantibody fingerprint', examination of epitope spreading and antibody isotype usage, discovery and characterization of candidate autoantigens, and tailoring antigen-specific therapy. In the coming decades, proteomics technologies will broaden our understanding of the underlying mechanisms of and will further our ability to diagnose, prognosticate and treat autoimmune disease.

    PMID:
    12223102
    [PubMed - indexed for MEDLINE]
    PMCID:
    PMC128938
    Free PMC Article

    Images from this publication.See all images (1)Free text

    Figure 1

      Supplemental Content

      Icon for BioMed Central Icon for PubMed Central

      Save items

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk